CLINICAL ANALYSIS OF HIGH-GRADE B-CELL LYMPHOMA IN 27 YOUNG AND MIDDLE-AGED PATIENTS

• Published in: 精准医学杂志 Vol. 38; no. 6; pp. 481 - 484
• Main Author: WANG Yuan, LYU Guiyang, ZHAO Peng, WANG Ling
• Format: Journal Article
• Language: Chinese
• Published: Editorial Office of Journal of Precision Medicine 01.12.2023
• Subjects: lymphoma, b-cell|chemotherapy, cancer, regional perfusion|progression-free survival|comparative effectiveness research|prognosis
• ISSN: 2096-529X
• DOI: 10.13362/j.jpmed.202306003

Objective To analyze the clinical features, therapeutic effects, and prognosis of high-grade B-cell lymphoma (HGBL) in young and middle-aged patients. Methods The clinical data of 27 young and middle-aged patients with HGBL were analyzed retrospectively. Results In 27 young and middle-aged patients with HGBL, advanced Ann Arbor stage, high age-adjusted international prognostic index score, many extranodal organ involvement, and bone marrow involvement were more common in patients with double/triple-hit lymphoma (HGBL-DT) compared with patients with HGBL, not otherwise specified (HGBL-NOS) (P<0.05). In the short-term efficacy comparison, the overall response rate of patients with HGBL-NOS was significantly higher than that of patients with HGBL-DT (P<0.05). In the long-term efficacy comparison, the progression free survival and overall survival of patients with HGBL-NOS were both significantly superior to those of patients with HGBL-DT (P<0.05). In 6 patients with early HGBL-NOS, remission was achieved in both